tbuckley/cabot-search huggingface dataset:
Abstract 18096: Novel Role of Caveolin-1 in Endothelial Function by Regulating Extracellular SOD Activity and Cu Transporter ATP7A Function
Authors: Sudhahar Varadarajan, Mustafa N Okur, John P O’Bryan, Richard D Minshall, Ronald D McKinney, Masuko Ushio-Fukai, Tohru Fukai
Journal: Circulation (2013)

Caveolin (Cav)-enriched lipid raft (C/LR) microdomains play an important role for regulating insulin signaling and endothelial function; however underlying mechanisms is incompletely understood. Vascular extracellular superoxide dismutase (ecSOD), a secretory copper (Cu) enzyme synthesized from vascular smooth muscle cells (VSMCs), preserves nitric oxide (NO)-mediated endothelial function by reducing extracellular superoxide anion (O2•-) levels. We previously demonstrated that Cu transporter ATP7A is required for full activity of ecSOD and that both ecSOD and ATP7A are found in C/LR. However, the functional significance of ATP7A-ecSOD pathway in insulin signaling and C/LR remains unknown. Here we show that in organoid culture of mouse aorta, insulin stimulation increases ecSOD specific activity (47%) and ATP7A expression. In cultured VSMCs, insulin stimulation promotes ATP7A translocation to the C/LR (1.7 fold) where ecSOD is activated by ATP7A through their binding. Furthermore, insulin stimulation promotes ATP7A association with Cav1 as shown by immunofluorescence and co-immunoprecipitation assay. Specific activity of ecSOD, but not Cu/Zn SOD, is significantly decreased (60%) in aorta of Cav1 knockout (KO) mice, indicating that Cav1 or C/LR is required for full ecSOD activity. Of note, ATP7A expression is decreased in aorta from Cav1 KO mice or Cav1-depleted VSMCs with siRNA, which is due to enhanced ATP7A ubiquitination. These results suggest that Cav1 binding to ATP7A at C/LR protects ATP7A from proteosomal degradation, thereby increasing ecSOD activity. Functionally, NO-dependent vasorelaxation induced by acetylcholine, but not NO-independent relaxation induced by sodium nitroprusside, is impaired in mesenteric arteries of Cav1 KO mice vs. wild type mice (P&lt;0.05), which is associated with overproduction of O2•- in the vessels and rescued by gene transfer of ecSOD. In summary, Cav1 plays an essential role for insulin-induced full ecSOD activation by regulating ATP7A translocation and expression. Our studies will provide novel insights into the Cav1-ATP7A-ecSOD axis as a potential therapeutic target for promoting endothelial function against oxidative stress-dependent cardiovascular and metabolic diseases.
DIAGNOSTIC ACCURACY OF ENDOFASTER IN DETECTION OF H. PYLORI INFECTION COMPARED TO GOLD STANDARD BIOPSY IN ROUTINE ENDOSCOPY
Authors: S Piccirelli, A Grassano, C Spada
Journal: Endoscopy (2020)

Hence, a novel diagnositc tool named EndoFaster-EF, by NISO Biomed, has been tested for diagnosis of HP and hypochlorhydria based on detection of ammonium and pH levels in gastric-juice in real-time during endoscopy.
Risks and Benefits of Marijuana Use
Authors: Salomeh Keyhani, Stacey Steigerwald, Julie Ishida, Marzieh Vali, Magdalena Cerdá, Deborah Hasin, Camille Dollinger, Sodahm R. Yoo, Beth E. Cohen
Journal: Annals of Internal Medicine (2018)

Although evidence is limited regarding the potential health benefits and safety of marijuana, legal access to it is increasing and marijuana products are being aggressively marketed to the public. ...
ENDOSCOPIC MANAGEMENT OF PANCREATIC NECROSIS USING THE ENDOROTOR
Authors: C Mangas-Sanjuan, M Bozhychko, L Medina-Prado, Sandra BM, B Martínez, JF Martínez, JA Casellas, JR Aparicio
Journal: Endoscopy (2020)

A 62 years-old-man with severe acute necrotizing pancreatitis had previously undergone unsuccessful conventional endoscopic management of pancreatic necrosis. Thereafter, we decided to use the EndoRotor system.It consists of a disposable catheter with a rotating blade at its distal end, which is connected to a suction and continuous irrigation pump. It is controlled by two pedals: one activates the rotation of the blade the other activates the aspiration. The removal of necrotic tissue is only performed when the aspiration is activated, which guarantees the safety and prevents complications. Three procedures using the EndoRotor were successfully carried out without adverse events.
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells
Authors: Hiroki Kimura, Dave Francisco, Michelle Conway, Fernando D. Martinez, Donata Vercelli, Francesca Polverino, Dean Billheimer, Monica Kraft
Journal: Journal of Allergy and Clinical Immunology (2020)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically changed our world, country, communities, and families. There is controversy regarding risk factors for severe COVID-19 disease. It has been suggested that asthma and allergy are not highly represented as comorbid conditions associated with COVID-19.Our aim was to extend our work in IL-13 biology to determine whether airway epithelial cell expression of 2 key mediators critical for SARS-CoV-2 infection, namely, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2), are modulated by IL-13.We determined effects of IL-13 treatment on ACE2 and TMPRSS2 expression ex vivo in primary airway epithelial cells from participants with and without type 2 asthma obtained by bronchoscopy. We also examined expression of ACE2 and TMPRSS2 in 2 data sets containing gene expression data from nasal and airway epithelial cells from children and adults with asthma and allergic rhinitis.IL-13 significantly reduced ACE2 and increased TMPRSS2 expression ex vivo in airway epithelial cells. In 2 independent data sets, ACE2 expression was significantly reduced and TMPRSS2 expression was significantly increased in the nasal and airway epithelial cells in type 2 asthma and allergic rhinitis. ACE2 expression was significantly negatively associated with type 2 cytokines, whereas TMPRSS2 expression was significantly positively associated with type 2 cytokines.IL-13 modulates ACE2 and TMPRSS2 expression in airway epithelial cells in asthma and atopy. This deserves further study with regard to any effects that asthma and atopy may render in the setting of COVID-19 infection.
Higher affinity antibodies elicit more potent ADCC
Authors: Yong Tang, Katherine Alpaugh, Jianlong Lou, Calvin Shaller, Gregory P. Adams, James D. Marks, Louis M. Weiner
Journal: Cancer Research (2006)

1172  Antibody-dependent cellular cytotoxicity (ADCC) is believed to be a major anti-tumor mechanism of some anti-cancer antibodies. However, the factors that regulate the magnitude of ADCC are incompletely understood. Herein, we describe the relationship between antibody affinity and ADCC. A series of human IgG1 antibodies was created from the anti-HER2/neu C6.5 scFv and its affinity mutants. The scFv affinities range from 10-7 to 10-11 M, and the IgG1 antibodies retain the affinities of the scFv from which they were derived. The apparent affinity (e.g., avidity) of the antibodies ranged from nearly 10-10 M (the lowest affinity variant) to almost 10-11 M (the other variants). The IgG molecules were tested for their ability to elicit ADCC in vitro against three tumor cell lines with differing levels of HER2/neu expression using unactivated human peripheral blood mononuclear cells (PBMC) from healthy donors as the effector cells. There is a clear influence of affinity on ADCC, with higher levels of peak cytotoxicity as apparent affinity approaches 10-11 M, and an affinity-dependent increase in cytotoxicity at lower antibody concentrations and lower effector: target ratios. These antibodies elicit more cytotoxicity against tumor cells expressing high levels of HER2/neu than against cells expressing lower amounts of HER2/neu. These findings justify the examination of high affinity antibodies for ADCC promotion, although the impaired tumor targeting associated with high affinity may be an important confounding factor in the design of unconjugated anti-tumor antibodies.
FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes
Authors: Asmerom T. Sengal, Ann-Marie Patch, Cameron E. Snell, Deborah S. Smith, Samuel C.Y. Leung, Aline Talhouk, Elizabeth D. Williams, Jessica N. McAlpine, Pamela M. Pollock
Journal: Clinical Cancer Research (2020)

Abstract Purpose: The two most common molecular subtypes of endometrial cancers, mismatch repair deficient (MMRd) and p53 wild-type (p53wt) comprise the majority of endometrial cancers and have intermediate prognoses where additional risk stratification biomarkers are needed. Isoform switching of FGFR2 from FGFR2b to FGFR2c (normally expressed in mesenchymal cells), has been reported in other solid carcinomas. The objective of this study was to investigate the role of FGFR2c in risk stratification of endometrial cancer. Experimental Design: We have developed and optimized a BaseScope RNA ISH assay to detect FGFR2c. FGFR2c expression was determined in a preliminary screening cohort of 78 endometrial cancers and a clinically and molecularly annotated Vancouver cohort (n = 465). Cox regression model analyses were performed to assess the prognostic value of FGFR2c. Results: Univariate and multivariate analyses revealed FGFR2c expression was significantly associated with shorter disease-specific survival (DSS) and progression-free survival (PFS) in endometrioid endometrial cancer (EEC, n = 302). Notably, FGFR2c expression was significantly associated with shorter PFS and DSS in patients with grade 3 EECs (P &amp;lt; 0.003 and P &amp;lt; 0.002) and the European Society Medical Oncology (ESMO) high-risk group (P &amp;lt; 0.0001 and P &amp;lt; 0.002), respectively. Moreover, within the MMRd subtype, FGFR2c expression was significantly associated with shorter PFS (P &amp;lt; 0.048) and DSS (P &amp;lt; 0.001). Conclusions: FGFR2c expression appears an independent prognostic biomarker in patients with EEC and further discerns the outcomes within grade 3 tumors, ESMO high-risk groups, as well as within the MMRd and p53wt subtypes. FGFR2c inclusion into future molecular subtyping can further refine risk stratification of EEC.
Durable response rates with talimogene laherparepvec or granulocyte-macrophage colony-stimulating factor are associated with additional clinical benefits in patients with stage IIIB-IVM1a melanoma in the OPTiM trial
Authors: K Harrington, Andtbacka Rhi., A Melcher, R Safaei, G Downey, H L Kaufman, M Middleton
Journal: British Journal of Dermatology (2016)
CONVOLUTIONAL NEURAL NETWORK BASED ALGORITHM FOR CECUM ACHIEVEMENT CONFIRMATION
Authors: S Kashin, D Zavyalov, A Rusakov, V Khryashchev, A Lebedev
Journal: Endoscopy (2020)

Aims Cecum intubation is the key criterion for the quality of colonoscopy. We tested the ability of computer-assisted image analysis using convolutional neural networks (CNNs) to confirm the achievement of the cecum.
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment
Authors: Iris M. Markusse, Gülşah Akdemir, Linda Dirven, Yvonne P.M. Goekoop-Ruiterman, Johannes H.L.M. van Groenendael, K. Huub Han, T.H. Esmeralda Molenaar, Saskia Le Cessie, Willem F. Lems, Peter A.H.M. van der Lubbe, Pit J.S.M. Kerstens, André J. Peeters, H. Karel Ronday, Peter B.J. de Sonnaville, Irene Speyer, Theo Stijnen, Saskia ten Wolde, Tom W.J. Huizinga, Cornelia F. Allaart
Journal: Annals of Internal Medicine (2016)

Studies have shown that a “treat-to-target” strategy results in improved clinical outcomes among patients with early active rheumatoid arthritis, but long-term data on this approach are lacking. Th...
Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation
Authors: Leena P. Bharath, Madhur Agrawal, Grace McCambridge, Dequina A. Nicholas, Hatice Hasturk, Jing Liu, Kai Jiang, Rui Liu, Zhenheng Guo, Jude Deeney, Caroline M. Apovian, Jennifer Snyder-Cappione, Gregory S. Hawk, Rebecca M. Fleeman, Riley M.F. Pihl, Katherine Thompson, Anna C. Belkina, Licong Cui, Elizabeth A. Proctor, Philip A. Kern, Barbara S. Nikolajczyk
Journal: Cell Metabolism (2020)
ERCP ADVERSE EVENTS: RARE CASES
Authors: A Denisova, P Zhegalov, A Samoylenko, V Melkomukov, N Antipenko, R Chashin, B Gomboev, Y Yazikova, P Popov, A Mislimova
Journal: Endoscopy (2020)

Aims Adverse events in ERCP are relatively rare (2,5-8%) but often life threatening. Many guidelines are published in order to minimize complication rate. Still some adverse events are hard to predict and prevent. The aim of the study was to analyze the ERCP complication rate and pay attention to rare ones.
Improving Blood Pressure Control through Provider Education, Provider Alerts, and Patient Education
Authors: Christianne L. Roumie, Tom A. Elasy, Robert Greevy, Marie R. Griffin, Xulei Liu, William J. Stone, Kenneth A. Wallston, Robert S. Dittus, Vincent Alvarez, Janice Cobb, Theodore Speroff
Journal: Annals of Internal Medicine (2006)

The authors randomly assigned providers caring for hypertensive patients to 1 of 3 interventions: 1) a Web link to the Seventh Report of the Joint National Committee on Prevention, Detection, Evalu...
Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward
Authors: Juliet E. Bryant, Andrew S. Azman, Matthew J. Ferrari, Benjamin F. Arnold, Maciej F. Boni, Yap Boum, Kyla Hayford, Francisco J. Luquero, Michael J. Mina, Isabel Rodriguez-Barraquer, Joseph T. Wu, Djibril Wade, Guy Vernet, Daniel T. Leung
Journal: Science Immunology (2020)

Defining acceptable performance characteristics for SARS-CoV-2 serological tests requires factoring in how the results will be used.
COLONOSCOPY QUALITY AFTER INTENSIVE TRAINING OF INEXPERIENCED ENDOSCOPISTS IN A NORWEGIAN SCREENING TRIAL FOR COLORECTAL CANCER
Authors: AL Schult, KR Randel, E Botteri, G Hoff, M Bretthauer, G Ursin, E Natvig, A Jørgensen, P Sandvei, MK Ek Olsen, SO Frigstad, O Darre-Næss, ER Norvard, H Kørner, A Wibe, T de Lange, Ø Holme
Journal: Endoscopy (2020)

Aims High-quality colonoscopies are essential to achieve an effective colorectal cancer (CRC) screening program. Limited colonoscopy capacity is a bottleneck for CRC screening. To inform the Norwegian health authorities of the feasibility of CRC screening, a screening pilot project was launched. Most of the endoscopists who performed the screening colonoscopies had little endoscopy experience and were given intensive training (one-to-one supervision by an experienced endoscopist) for three to six months before performing endoscopies. The aim of this work is to show colonoscopy performance of inexperienced endoscopists.
Comparative Effectiveness of Clostridium difficile Treatments
Authors: Dimitri M. Drekonja, Mary Butler, Roderick MacDonald, Donna Bliss, Gregory A. Filice, Thomas S. Rector, Timothy J. Wilt
Journal: Annals of Internal Medicine (2011)

The incidence and severity of Clostridium difficile infections are increasing, and several antibiotics are available for treatment. This comparative effectiveness review of 11 randomized trials inv...
OUTCOMES OF ENTEROSCOPY-ASSISTED DIRECT PERCUTANEOUS ENDOSCOPIC JEJUNOSTOMY (DPEJ) TUBE PLACEMENT - A SINGLE-CENTER EXPERIENCE
Authors: K Soota, MM Abdelfatah, S Gulati, A Ahmed, KRKK Baig, S Peter
Journal: Endoscopy (2020)

Aims Review our clinical experience of direct percutaneous endoscopic jejunostomy (DPEJ) in a tertiary care center.
ENDOSCOPIC VACUUM-ASSISTED CLOSURE THERAPY FOR NECROTIZING INFECTION AFTER PELVIC EXENTERATION
Authors: CF Gomes, C Palmela, R Loureiro, S Ouro, E Barjas, L Glória, M Cravo
Journal: Endoscopy (2020)

A 52-year-old female patient, with a personal history of cervical cancer, presented a lymphatic relapse with mesorectum and left ureter invasion, after 8 years of follow-up. In the postoperative period of pelvic exenteration, the patient presented fever and exudate drainage through the vagina. CT scan revealed a pelvic necrotic cavity that communicated with the vagina. Intravenous antibiotics were initiated, as well as endoscopic vacuum-assisted closure therapy through the vagina. After 13 sessions of vacuum therapy, the patient was discharged. During an 18-month follow-up the patient remained asymptomatic and endoscopic evaluation showed a residual cavity with no infectious sings.
DEVELOPMENT AND CLINICAL IMPLEMENTATION OF AN ENDOCYTOSCOPY SCORING SYSTEM OF DYSPLASIA IN THE BARRETT’S ESOPHAGUS: PRELIMINARY RESULTS
Authors: JJH van der Laan, X Zhao, I Schmidt, RY Gabriëls, A Karrenbeld, FTM Peters, J Westerhof, WB Nagengast
Journal: Endoscopy (2020)

Aims To evaluate the diagnostic capability of endocytoscopy (ECS) [model GIF-H290 EC, Olympus] in detecting dysplasia in Barrett’s esophagus (BE).
General anesthetics activate a potent central pain-suppression circuit in the amygdala
Authors: Thuy Hua, Bin Chen, Dongye Lu, Katsuyasu Sakurai, Shengli Zhao, Bao-Xia Han, Jiwoo Kim, Luping Yin, Yong Chen, Jinghao Lu, Fan Wang
Journal: Nature Neuroscience (2020)
A novel platform for radioimmunotherapy. Extracorporeal depletion of biotinylated and <sup>90</sup>Y-labeled anti-CD20 in patients with refractory B-cell lymphoma
Authors: O. Linden, J. Kurkus, M. Garkavij, E. Cavallin-Ståhl, T. Ohlsson, R. Nilsson, B. E. Sandberg, M. Ljungberg, S.-E. Strand, J. Tennvall
Journal: Journal of Clinical Oncology (2004)

6576 Background: Radioimmunotherapy is limited by the absorbed dose to radiosensitive organs. The bone marrow is the first dose limiting organ and the absorbed dose to it is mainly derived from unbound radiolabeled MAb in the circulation. A removal of these circulating MAb should, in patients (pts) with a not heavily infiltrated bone marrow, permit the administration of higher amounts of radioactivity. This would then translate into a higher dose to the tumor. Method: A lymphoma setting was chosen to test the feasibility of the adsorption procedure, (ECAT). A novel device MitraDep® was tested, by which biotinylated and radiolabeled MAb can be removed from the circulation, when whole blood is passed over a filter coated with avidin .The MAbs were radiolabeled and biotinylated using MitraTag™, a moiety consisting of DOTA and biotin. Pts with refractory B-cell lymphoma received infusions with 250mg/m2 cold rituximab and 150 MBq 111In-anti-CD20-biotin for targeting. A week later pts were treated with another 250mg/m2 rituximab followed by injection of 11–15 MBq/kg 90Y-anti-CD20-biotin. 40 to 48 h later ECAT was performed. Results: All 8 pts receiving 111In-anti-CD20-biotin showed clear tumor uptake. One patient had an allergic reaction and did therefore not proceed. The other 7 pts received RIT and subsequent ECAT. The mean depletion of 90Y-anti-CD20-biotin in whole blood after ECAT was 96% (range 92–98%). The depletion of 90Y in the lungs was 62%, in the liver and kidneys 40%. No effects on pts'vital signs, no adverse effects on hematological or coagulation parameters and no significant complement or bradykinin activation were observed during ECAT. 3 of 7 pts exhibited an objective response. Conclusion: The ECAT procedure using MitraDep was efficient, safe and reproducible. Biotinylated 111In antiCD20 MAb targeted in all cases and seems safe. 90Y-anti-CD20-biotin preceded by rituximab and followed by ECAT can induce objective remissions in pts with refractory B-cell lymphoma. Based on the effectiveness of the depletion and absence of significant adverse effects a dose-escalation study will be initiated. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Mitra Medical Technology AB Mitra Medical Technology AB
MOSE FOR EUS-GUIDED PANCREATIC TISSUE ACQUISITION: THE THIRD WAY
Authors: T Togliani, I Breoni, V Davì, N Mantovani, A Savioli, E Vitetta, S Pilati
Journal: Endoscopy (2020)

Aims To increase FNA performance ROSE and the use of core needles have been extensively analyzed. The aim of this study was to assess the role of the macroscopic on-site evaluation (MOSE) to raise the adequacy of pancreatic FNA.
THERMAL ABLATION OF THE MUCOSAL DEFECT MARGIN AFTER ENDOSCOPIC MUCOSAL RESECTION SIGNIFICANTLY REDUCES ADENOMA RECURRENCE - A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRE TRIAL
Authors: M Sidhu, DJ Tate, L Hourigan, S Raftopoulos, A Moss, S Heitman, N Shahidi, NG Burgess, E Lee, S Williams, MJ Bourke
Journal: Endoscopy (2020)

Aims Thermal ablation of the defect margin (TAM) after endoscopic mucosal resection (EMR) in the treatment of large (≥20mm) laterally spreading lesions (LSL) has been shown to be efficacious in a clinical trial setting, with a four-fold reduction, in residual or recurrent adenoma (RRA) at 6 months first surveillance colonoscopy (SC1). The clinical effectiveness of this treatment is unknown.
DYE-BASED CHROMOENDOSCOPY VERSUS STANDARD-DEFINITION AND HIGH-DEFINITION WHITE-LIGHT ENDOSCOPY FOR ENDOSCOPIC ADENOMA DETECTION IN LYNCH SYNDROME: META-ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMISED TRIALS
Authors: BBSL Houwen, NS. Mostafavi, JLA Vleugels, R Hüneburg, C Lamberti, L Rivero-Sánchez, M Pellisé, E Stoffel, S Syngal, JF Haanstra, JJ Koornstra, E Dekker, Y Hazewinkel
Journal: Endoscopy (2020)

Aims The additional diagnostic value of dye-based chromoendoscopy (CE) compared to standard-definition and high-definition white-light endoscopy (SD-WLE and HD-WLE) for surveillance of Lynch syndrome (LS) patients is subject to debate. To clarify this debate, an individual patient data (IPD) meta-analysis was performed.
Treatment of Myelodysplastic Syndromes with Recombinant Human Granulocyte Colony-Stimulating Factor
Authors: Robert S. Negrin
Journal: Annals of Internal Medicine (1989)

Study Objective: To determine the hematopoietic effects and toxicity of recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with myelodysplastic syndromes. Design: The G-CSF was administered by daily subcutaneous injection to outpatients in a phase I-II trial. Dose was escalated every 2 weeks between 0.1 to 3.0 μg/kg body weight d over an 8-week treatment period. Setting: Outpatient clinical research center at a university hospital. Patients: Twelve consecutive patients with myelodysplastic syndromes: two refractory anemia, seven refractory anemia with excess of blasts, three refractory anemia with excess of blasts in transformation. Measurements and Main Results: In 10 of 12 patients, elevations in blood leukocyte counts (2- to 10-fold) and absolute neutrophil counts (5- to 40-fold) were seen over the 8-week treatment period. Five of seven severely neutropenic patients (absolute neutrophil count, < 0.5 X 109/L) had a rise in count to 1.2 to 16.3 X 10VL. Increased reticulocyte counts occurred in 5 patients, and were associated with decreased transfusion requirements in 2 of 9 erythrocyte transfusion-dependent patients. Treatment with G-CSF enhanced marrow myeloid cell maturation in 9 of 11 evaluable patients. Neutrophil Chemotaxis and phagocytosis in vitro were improved or unchanged after treatment in 6 of 8 patients tested. In 11 of 12 patients, there were no substantial changes in platelet, lymphocyte, eosinophil, or monocyte counts. Three responding patients initially had abnormal cytogenetics that persisted after G-CSF therapy, suggesting induced differentiation of the abnormal clone. The therapy was associated with minimal toxicity. None of the patients' conditions converted to acute leukemia during treatment or in short-term follow-up. Conclusions: Treatment with G-CSF administered by subcutaneous injection is well tolerated and effective for improving the neutropenia, and less commonly the transfusion-dependent anemia, over 6 to 8 weeks in patients with myelodysplastic syndromes.
COVERT CANCER IN COLORECTAL POLYPS - SIZE MATTERS!
Authors: E Hossain, S Thayalasekaran, AAl kandari, S Subramaniam, L Varytimiadis, M Abdelrahim, S Arndtz, P Bhandari
Journal: Endoscopy (2020)

Aims To demonstrate the risk of covert cancer in colorectal polyps based on their size in one of the largest series of polyps to date